Connect Biopharma Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Portfolio Pulse from
Connect Biopharma (CNTB) received a Nasdaq deficiency notice for its stock price falling below the $1.00 minimum requirement. The company has 180 days (until September 22, 2025) to regain compliance, with potential for an additional 180-day extension if certain conditions are met. Failure to comply could result in delisting.
March 28, 2025 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Company must raise stock price above $1.00 by September 22, 2025, or risk being removed from Nasdaq Global Market. Potential actions include stock reverse split or strategic financial moves.
Nasdaq deficiency notice directly impacts CNTB's stock, signaling potential financial and market perception challenges. Failure to regain compliance could lead to forced delisting, negatively affecting investor confidence and stock valuation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
Nasdaq demonstrates commitment to maintaining listing quality standards by issuing compliance notice to Connect Biopharma.
Routine enforcement of listing rules by Nasdaq, with minimal direct financial impact on NDAQ itself. Represents standard market governance procedure.
CONFIDENCE 70
IMPORTANCE 20
RELEVANCE 30